Nu Skin Enterprises Inc. (NUS): Today's Featured Consumer Non-Durables Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Nu Skin ( NUS) pushed the Consumer Non-Durables industry lower today making it today's featured Consumer Non-Durables laggard. The industry as a whole was unchanged today. By the end of trading, Nu Skin fell $1.01 (-2.4%) to $41.73 on average volume. Throughout the day, 1.6 million shares of Nu Skin exchanged hands as compared to its average daily volume of 1.5 million shares. The stock ranged in price between $41.72-$43.02 after having opened the day at $42.58 as compared to the previous trading day's close of $42.74. Other companies within the Consumer Non-Durables industry that declined today were: Summer Infant ( SUMR), down 18.1%, Deckers Outdoor Corporation ( DECK), down 6%, Xerium Technologies ( XRM), down 5%, and Forward Industries ( FORD), down 4.8%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements worldwide. The company sells its personal care products under the Nu Skin brand; and nutritional supplements under the Pharmanex brand. Nu Skin has a market cap of $2.56 billion and is part of the consumer goods sector. The company has a P/E ratio of 13.5, equal to the average consumer non-durables industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 12% year to date as of the close of trading on Tuesday. Currently there are seven analysts that rate Nu Skin a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Nu Skin as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the consumer non-durables industry could consider Consumer Staples Select Sector SPDR ( XLP) while those bearish on the consumer non-durables industry could consider ProShares Ultra Sht Consumer Goods ( SZK).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing